Skip to main content

Juvisync Side Effects

Generic name: simvastatin / sitagliptin

Medically reviewed by Drugs.com. Last updated on Feb 6, 2024.

Note: This document provides detailed information about Juvisync Side Effects associated with simvastatin / sitagliptin. Some dosage forms listed on this page may not apply specifically to the brand name Juvisync.

Applies to simvastatin / sitagliptin: oral tablet.

Important warnings This medicine can cause some serious health issues

You should not use this medicine if you have liver disease or severe kidney disease. Do not use if you are in a state of diabetic ketoacidosis (call your doctor for treatment with insulin).

Do not use simvastatin and sitagliptin if you are pregnant, and stop taking the medicine if you become pregnant.

Do not use simvastatin and sitagliptin if you are breast-feeding.

There are many other drugs that should not be used together with simvastatin and sitagliptin. Tell your doctor about all other medicines you use.

Do not consume grapefruit products while taking simvastatin and sitagliptin.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

In rare cases, simvastatin and sitagliptin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.

Stop using simvastatin and sitagliptin and call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to simvastatin / sitagliptin: oral tablet.

General

Simvastatin:

Dermatologic

Simvastatin:

Simvastatin-sitagliptin:

Endocrine

Simvastatin:

Genitourinary

Simvastatin:

Simvastatin-sitagliptin:

Hematologic

Simvastatin:

Simvastatin-sitagliptin:

Elevation of CK levels of 3 or more times the normal value has been reported. This was attributable to the noncardiac fraction of CK.

Musculoskeletal

Simvastatin:

Simvastatin-sitagliptin:

Sitagliptin: Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database. Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor. In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain. In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation. A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor. Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).[Ref]

Gastrointestinal

Simvastatin:

Simvastatin-sitagliptin:

Sitagliptin

Cardiovascular

Simvastatin:

Metabolic

Sitagliptin:

Nervous system

Simvastatin:

Sitagliptin:

Simvastatin-sitagliptin:

Respiratory

Simvastatin:

Sitagliptin:

Simvastatin-sitagliptin:

Hepatic

Simvastatin-sitagliptin:

Simvastatin

Hypersensitivity

Simvastatin:

Sitagliptin:

Renal

Simvastatin-sitagliptin:

Psychiatric

Simvastatin:

Simvastatin-sitagliptin:

Cognitive impairment is reversible up on statin discontinuation.

References

1. (2011) "Product Information. Juvisync (simvastatin-sitagliptin)." Merck & Co., Inc

2. US Food and Drug Administration (2015) FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf

Further information

Juvisync side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.